SAREPTA THERAPEUTICS INC revenue for the last year amounted to 1.13 B EUR, the most of which — 1.13 B EUR — came from its highest performing source at the moment, RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities, the year earlier bringing 871.77 M EUR. The greatest contribution to the revenue figure was made by United States — last year it brought SAREPTA THERAPEUTICS INC 1.13 B EUR, and the year before that — 871.77 M EUR.